A Phase 1 interventional study of Apremilast and Placebo in Pharmacokinetics, sponsored by Amgen. Completed at 1 site in Korea, Republic of. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-06.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This two-part study was designed to evaluate the pharmacokinetics (PK) of single and multiple doses of apremilast in healthy adult Korean males.
The study will consist of two parts. Part 1 will evaluate the PK of ascending single doses of apremilast. Part 2 will evaluate the PK of apremilast when administered as multiple doses over 14 days.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Vital signs (systolic and diastolic blood pressure, pulse rate, and oral [or tympanic] body temperature) will be assessed in the supine position after the subject has rested for at least five minutes. Subject must be afebrile (febrile [oral or tympanic] is defined as ≥ 38°C or 100.3°F) with vital signs within the following ranges:
Requirements:
Exclusion Criteria:
The presence of any of the following will exclude any healthy subject from enrollment into the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single oral dose of 20 mg apremilast.
Drug: Apremilast
A single oral dose of 30 mg apremilast.
Drug: Apremilast
A single oral dose of 40 mg apremilast.
Drug: Apremilast
30 mg apremilast orally twice a day (BID) for 14 days.
Drug: Apremilast
Matching placebo orally twice a day for 14 days.
Drug: Placebo
Tablet for oral administration
Also known as: CC-10004, OTEZLA®
Tablet for oral administration
Part 1: Maximum Observed Plasma Concentration (Cmax) of Apremilast
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.
Time frame: Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.
Part 1: Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast
Time frame: Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast
Time frame: Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) for Apremilast
Time frame: Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.
Part 1: Terminal Elimination Half-life (T1/2) for Apremilast
Time frame: Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.
Part 1: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)
Time frame: Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.
Part 1: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)
Time frame: Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.
Part 2: Area Under the Plasma Concentration-time Curve During a Dosage Interval (AUCτ) for Apremilast
Area under the plasma concentration-time curve during a dosage interval (tau) at steady state, where tau is 12 hours.
Time frame: Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose
Part 2: Maximum Observed Plasma Concentration (Cmax) of Apremilast
Time frame: Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose
Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast
Time frame: Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose
Part 2: Terminal Elimination Half-life (T1/2) for Apremilast
Time frame: Day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours after the morning dose
Part 2: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)
Time frame: Day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours after the morning dose
Part 2: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)
Time frame: Day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours after the morning dose
Part 2: Ratio of Accumulation
Ratio of accumulation calculated as Day 14 AUC0-τ / Day 1 AUC0-τ
Time frame: Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose, and on day 14 only at 24, 36, 48, 60, and 72 hours after the morning dose
Number of Participants With Treatment-emergent Adverse Events (AEs)
Time frame: Part 1, up to 40 days; Part 2, up to 24 days
This was a two-part study in healthy Korean men. The study was conducted at 1 clinic in Korea.
| Milestone | Part 1: Apremilast 20 mg / 30 mg / 40 mg | Part 1: Apremilast 30 mg / 20 mg / 40 mg | Part 1: Apremilast 40 mg / 20 mg / 30 mg | Part 2: Apremilast 30 mg BID | Part 2: Placebo BID |
|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 12 | 4 |
| Completed | 4 | 3 | 4 | 12 | 4 |
| Not completed | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.
| ng/mL | Part 1: Apremilast 20 mg | Part 1: Apremilast 30 mg | Part 1: Apremilast 40 mg |
|---|---|---|---|
| Part 1: Maximum Observed Plasma Concentration (Cmax) of Apremilast | 205 ± 32.1 | 273 ± 32.1 | 373 ± 19.7 |
| hours | Part 1: Apremilast 20 mg | Part 1: Apremilast 30 mg | Part 1: Apremilast 40 mg |
|---|---|---|---|
| Part 1: Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast | 3.0 (1.5 to 5.0) | 3.0 (1.5 to 5.0) | 2.0 (0.5 to 5.0) |
| ng*hr/mL | Part 1: Apremilast 20 mg | Part 1: Apremilast 30 mg | Part 1: Apremilast 40 mg |
|---|---|---|---|
| Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast | 1770 ± 25.8 | 2330 ± 22.6 | 3470 ± 25.7 |
| ng*hr/mL | Part 1: Apremilast 20 mg | Part 1: Apremilast 30 mg | Part 1: Apremilast 40 mg |
|---|---|---|---|
| Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) for Apremilast | 1790 ± 25.5 | 2360 ± 22.1 | 3500 ± 25.6 |
| hours | Part 1: Apremilast 20 mg | Part 1: Apremilast 30 mg | Part 1: Apremilast 40 mg |
|---|---|---|---|
| Part 1: Terminal Elimination Half-life (T1/2) for Apremilast | 7.4 ± 35.2 | 8.2 ± 44.4 | 7.4 ± 36.8 |
| liters/hour | Part 1: Apremilast 20 mg | Part 1: Apremilast 30 mg | Part 1: Apremilast 40 mg |
|---|---|---|---|
| Part 1: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) | 11.1 ± 25.5 | 12.7 ± 22.1 | 11.4 ± 25.6 |
| liters | Part 1: Apremilast 20 mg | Part 1: Apremilast 30 mg | Part 1: Apremilast 40 mg |
|---|---|---|---|
| Part 1: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F) | 120 ± 47.6 | 151 ± 49.6 | 122 ± 38.7 |
Area under the plasma concentration-time curve during a dosage interval (tau) at steady state, where tau is 12 hours.
| ng*hr/mL | Part 2: Apremilast 30 mg BID |
|---|---|
| Day 1 | 1610 ± 33.0 |
| Day 14 | 2600 ± 34.3 |
| ng/mL | Part 2: Apremilast 30 mg BID |
|---|---|
| Day 1 | 283 ± 34.3 |
| Day 14 | 408 ± 36.5 |
| hours | Part 2: Apremilast 30 mg BID |
|---|---|
| Day 1 | 2.00 (1.00 to 5.00) |
| Day 14 | 1.50 (1.00 to 3.00) |
| hours | Part 2: Apremilast 30 mg BID |
|---|---|
| Part 2: Terminal Elimination Half-life (T1/2) for Apremilast | 7.80 ± 31.4 |
| liters/hour | Part 2: Apremilast 30 mg BID |
|---|---|
| Part 2: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) | 11.5 ± 34.3 |
| liters | Part 2: Apremilast 30 mg BID |
|---|---|
| Part 2: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F) | 130 ± 53.3 |
Ratio of accumulation calculated as Day 14 AUC0-τ / Day 1 AUC0-τ
| ratio | Part 2: Apremilast 30 mg BID |
|---|---|
| Part 2: Ratio of Accumulation | 1.62 ± 36.0 |
| Participants | Part 1: Apremilast 20 mg | Part 1: Apremilast 30 mg | Part 1: Apremilast 40 mg | Part 2: Apremilast 30 mg BID | Part 2: Placebo BID |
|---|---|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 2 | 1 | 3 | 7 | 3 |
| TEAE related to study drug | 1 | 1 | 2 | 6 | 2 |
| Serious adverse events | 0 | 0 | 0 | 0 | 0 |
| Serious adverse events related o study dug | 0 | 0 | 0 | 0 | 0 |
| TEAE leading to discontinuation | 0 | 0 | 0 | 0 | 0 |
| Treatment-related TEAE leading to discontinuation | 0 | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 | 0 |
Collected over Part 1, up to 40 days; Part 2, up to 24 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Apremilast 20 mg | — | 0/11 (0%) | 2/11 (18.2%) |
| Part 1: Apremilast 30 mg | — | 0/12 (0%) | 1/12 (8.3%) |
| Part 1: Apremilast 40 mg | — | 0/12 (0%) | 3/12 (25%) |
| Part 1: Total | — | 0/12 (0%) | 4/12 (33.3%) |
| Part 2: Apremilast 30 mg BID | — | 0/12 (0%) | 7/12 (58.3%) |
| Part 2: Placebo BID | — | 0/4 (0%) | 3/4 (75%) |
| Part 2: Total | — | 0/16 (0%) | 10/16 (62.5%) |
| Event | Part 1: Apremilast 20 mg | Part 1: Apremilast 30 mg | Part 1: Apremilast 40 mg | Part 1: Total | Part 2: Apremilast 30 mg BID | Part 2: Placebo BID | Part 2: Total |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/11 | 0/12 | 0/12 | 0/12 | 4/12 | 1/4 | 5/16 |
| Upper respiratory tract infectionInfections and infestations | 0/11 | 0/12 | 0/12 | 0/12 | 3/12 | 1/4 | 4/16 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/11 | 0/12 | 0/12 | 0/12 | 1/12 | 1/4 | 2/16 |
| RashSkin and subcutaneous tissue disorders | 0/11 | 0/12 | 0/12 | 0/12 | 1/12 | 1/4 | 2/16 |
| DiarrhoeaGastrointestinal disorders | 1/11 | 1/12 | 1/12 | 1/12 | 2/12 | 0/4 | 2/16 |
| NauseaGastrointestinal disorders | 0/11 | 0/12 | 2/12 | 2/12 | 0/12 | 0/4 | 0/16 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/11 | 0/12 | 0/12 | 1/12 | 0/12 | 0/4 | 0/16 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 1/11 | 1/12 | 0/12 | 1/12 | 1/12 | 0/4 | 1/16 |
| Abdominal pain upperGastrointestinal disorders | 0/11 | 0/12 | 0/12 | 0/12 | 1/12 | 0/4 | 1/16 |
| Skin abrasionInjury, poisoning and procedural complications | 0/11 | 0/12 | 0/12 | 0/12 | 1/12 | 0/4 | 1/16 |
All enrolled participants
| Age, Continuous(years) | Part 1: Apremilast | Part 2: Apremilast 30 mg BID | Part 2: Placebo BID | Total |
|---|---|---|---|---|
| Mean | 29.8 (19.0 to 43.0) | 30.8 (24.0 to 41.0) | 25.5 (20.0 to 31.0) | 29.6 (19.0 to 43.0) |
| Sex: Female, Male(Participants) | Part 1: Apremilast | Part 2: Apremilast 30 mg BID | Part 2: Placebo BID | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 12 | 12 | 4 | 28 |
| Race/Ethnicity, Customized(Participants) | Part 1: Apremilast | Part 2: Apremilast 30 mg BID | Part 2: Placebo BID | Total |
|---|---|---|---|---|
| Asian | 12 | 12 | 4 | 28 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jun 2016 to primary completion in Aug 2016, 1 month.
Results were first posted in Jul 2021, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast